Pharmacology · Cardiovascular

Hypertension in Chronic Kidney Disease

Pathophysiology, renoprotective pharmacology, and the emerging triple strategy

Hypertension and chronic kidney disease form a self-amplifying cycle: nephron loss reduces natriuretic capacity, ischemic nephrons release renin inappropriately, and renal afferent nerve signals drive sympathetic activation — all three mechanisms raise blood pressure, which then accelerates glomerulosclerosis and further nephron loss through intraglomerular hypertension and proteinuria-driven tubular inflammation.
RAAS inhibitors are first-line for all CKD with albuminuria above 30 mg/g because they provide renoprotection by mechanisms independent of blood pressure reduction: dilation of the efferent arteriole reduces intraglomerular pressure, direct reduction of glomerular filtration barrier permeability decreases proteinuria, and blockade of angiotensin II-driven TGF-beta production slows interstitial fibrosis.
A creatinine rise of up to 30 percent after starting a RAAS inhibitor is expected and acceptable — it reflects successful reduction of intraglomerular pressure, which is the mechanism of renoprotection, not a sign of nephrotoxicity; rises above 50 percent warrant holding the drug and investigating for bilateral renal artery stenosis or volume depletion.
Drug selection shifts as eGFR falls: thiazides lose diuretic efficacy below eGFR 30, where loop diuretics become first-line; potassium-sparing agents require extreme caution in Stage 4 CKD; fosinopril and telmisartan are preferred RAAS inhibitors in advanced CKD due to dual or biliary elimination; calcium channel blockers remain effective and safe at all stages.
In type 2 diabetic CKD, guidelines now support a triple renoprotective strategy targeting three distinct pathways: RAAS inhibitors for efferent arteriolar dilation and antifibrosis, SGLT2 inhibitors for restoration of tubuloglomerular feedback and afferent arteriolar constriction, and finerenone (a non-steroidal MRA) for aldosterone-mediated renal inflammation and fibrosis — with a combined reduction in major adverse kidney events now supported by CREDENCE, DAPA-CKD, and FIDELIO-DKD.

Abbreviations: CKD = chronic kidney disease · HTN = hypertension · RAAS = renin-angiotensin-aldosterone system · ACEi = angiotensin converting enzyme inhibitor · ARB = angiotensin receptor blocker · eGFR = estimated glomerular filtration rate · ESRD = end-stage renal disease · CCB = calcium channel blocker · MRA = mineralocorticoid receptor antagonist · SGLT2 = sodium-glucose cotransporter 2 · TGF-beta = transforming growth factor beta · NSAIDs = nonsteroidal anti-inflammatory drugs · mEq/L = milliequivalents per liter · ADA = American Diabetes Association · KDIGO = Kidney Disease: Improving Global Outcomes

The Chronic Kidney Disease-Hypertension Bidirectional Cycle

Self-Amplifying — Each Side Worsens the Other

How Chronic Kidney Disease Drives Hypertension

Nephron Loss

Reduced natriuretic capacity → sodium and water retention → volume-dependent hypertension

RAAS Activation

Ischemic nephrons release renin inappropriately → angiotensin II → vasoconstriction + aldosterone → more sodium retention

Sympathetic Activation

Renal afferent nerve signals from damaged kidney → increased sympathetic outflow → raises cardiac output and peripheral resistance

↓ All three mechanisms elevate systemic blood pressure ↓

Intraglomerular HTN

Elevated glomerular capillary pressure from hyperfiltration and efferent constriction

Proteinuria

Filtered proteins activate tubular inflammation and fibrosis — nephrotoxic

More Nephron Loss

Tubular injury → interstitial fibrosis → glomerulosclerosis → cycle repeats

RAAS Inhibitor Renoprotection & Monitoring

Mechanism Beyond Blood Pressure

Why RAAS Inhibitors Protect the Kidney

Angiotensin II constricts efferent arteriole → raises intraglomerular pressure; RAAS inhibitors dilate efferent arteriole → reduce intraglomerular pressure → less proteinuria and less glomerulosclerosis
Reduce glomerular filtration barrier permeability (independent of pressure effect)
Block angiotensin II-driven transforming growth factor beta production → less interstitial fibrosis
First-line for all CKD with albuminuria above 30 mg/g (KDIGO 2021 Category A)
Do NOT combine ACEi + ARB: VA NEPHRON-D — excess acute kidney injury, no renal benefit

Monitoring After Initiation

The Acceptable Creatinine Rise

Check creatinine, eGFR, potassium at 2–4 weeks
Rise up to 30%: expected and acceptable — reflects reduced intraglomerular pressure (the goal)
Rise 30–50%: check for volume depletion, NSAIDs, contrast; consider dose reduction
Rise above 50%: hold drug, reassess, restart at lower dose
Potassium above 5.5 mEq/L: dose reduction or discontinuation
Sick-day rule: hold RAAS inhibitor + diuretic during vomiting, diarrhea, or fever

Drug Selection Across Chronic Kidney Disease Stages

Key Transitions: Thiazide Efficacy Falls, Loop Diuretics Replace, Potassium Risk Rises

Stage-by-Stage Prescribing Guide

Stage / eGFR	RAAS Inhibitor	Diuretic	Other Notes
Stage 1–2 eGFR ≥60	ACEi or ARB if albuminuria above 30 mg/g; optional without albuminuria	Thiazide or thiazide-like — full efficacy	Standard four-class framework; target below 130/80
Stage 3 eGFR 30–59	Continue if tolerated; first-line with albuminuria	Chlorthalidone or indapamide preferred; transition to loop diuretic at eGFR 30–45 if volume control inadequate	CCBs (amlodipine) highly effective — no dose adjustment; monitor potassium every 3 months
Stage 4 eGFR 15–29	Continue if potassium below 5.0; fosinopril (ACEi) or telmisartan (ARB) preferred — dual or biliary elimination	Loop diuretics first-line; torsemide preferred (better bioavailability)	Spironolactone/eplerenone: extreme caution (hyperkalemia); bisoprolol preferred beta-blocker (dual elimination)
Stage 5 / ESRD eGFR below 15	Continue for cardiovascular protection if potassium manageable; telmisartan or candesartan preferred (not dialyzed)	High-dose loop diuretics pre-dialysis; ultrafiltration on hemodialysis	Volume control dominates; CCBs effective and safe at all stages

Emerging Triple Renoprotective Strategy — Type 2 Diabetic CKD

RAAS Inhibitor

ACEi or ARB
Dilates efferent arteriole → reduces intraglomerular pressure
Blocks angiotensin II fibrosis (TGF-beta)
Lewis 1993; RENAAL; IDNT; REIN

SGLT2 Inhibitor

Canagliflozin, Dapagliflozin, Empagliflozin
Restores tubuloglomerular feedback → afferent constriction → reduces intraglomerular pressure
CREDENCE (−40%); DAPA-CKD (−39%); EMPA-KIDNEY (−28%)

Finerenone

Non-steroidal MRA
Blocks aldosterone-mediated inflammation and fibrosis at mineralocorticoid receptor
Lower hyperkalemia risk than spironolactone; no sex hormone effects
FIDELIO-DKD: −18% renal composite

Why Three Drugs? Three Complementary Targets

Each agent targets a distinct driver of progressive nephron loss in type 2 diabetic CKD. RAAS inhibitors reduce efferent arteriolar tone and angiotensin II-driven fibrosis. SGLT2 inhibitors restore tubuloglomerular feedback, reducing afferent arteriolar pressure. Finerenone blocks aldosterone-mediated renal inflammation and fibrosis. Together they address all three major pathways — and their combination is supported by guideline recommendations from KDIGO and ADA.

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group	KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease	Kidney Int. 2021;99(3S):S1–S87
Whelton PK, Carey RM, Aronow WS, et al.	2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults	J Am Coll Cardiol. 2018;71(19):e127–e248
Brenner BM, Cooper ME, de Zeeuw D, et al.	Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL)	N Engl J Med. 2001;345(12):861–869
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD	The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy	N Engl J Med. 1993;329(20):1456–1462
Lewis EJ, Hunsicker LG, Clarke WR, et al.	Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (IDNT)	N Engl J Med. 2001;345(12):851–860
Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN)	Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy (REIN trial)	Lancet. 1997;349(9069):1857–1863
Agarwal R, Sinha AD, Cramer AE, et al.	Chlorthalidone for hypertension in advanced chronic kidney disease (CLICK trial)	N Engl J Med. 2021;385(27):2507–2519
Heerspink HJL, Stefansson BV, Correa-Rotter R, et al.	Dapagliflozin in patients with chronic kidney disease (DAPA-CKD)	N Engl J Med. 2020;383(15):1436–1446
Williams B, Mancia G, Spiering W, et al.	2018 ESC/ESH guidelines for the management of arterial hypertension	Eur Heart J. 2018;39(33):3021–3104
Perkovic V, Jardine MJ, Neal B, et al.	Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE)	N Engl J Med. 2019;380(24):2295–2306
Bakris GL, Agarwal R, Anker SD, et al.	Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD)	N Engl J Med. 2020;383(23):2219–2229
Fried LF, Emanuele N, Zhang JH, et al.	Combined angiotensin inhibition for the treatment of diabetic nephropathy (VA NEPHRON-D)	N Engl J Med. 2013;369(20):1892–1903
Mancia G, Kreutz R, Brunstrom M, et al.	2023 ESH guidelines for the management of arterial hypertension	J Hypertens. 2023;41(12):1874–2071
Wheeler DC, Stefansson BV, Jongs N, et al.	Effects of dapagliflozin on major adverse kidney events in patients with diabetic and non-diabetic chronic kidney disease (DAPA-CKD prespecified analysis)	Lancet Diabetes Endocrinol. 2021;9(1):22–31